Journal article

Engineered Human Heavy-Chain Ferritin with Half-Life Extension and Tumor Targeting by PAS and RGDK Peptide Functionalization

Shuang Yin, Yan Wang, Bingyang Zhang, Yiran Qu, Yongdong Liu, Sheng Dai, Yao Zhang, Yingli Wang, Jingxiu Bi

PHARMACEUTICS | MDPI | Published : 2021

Abstract

Ferritin, one of the most investigated protein nanocages, is considered as a promising drug carrier because of its advantageous stability and safety. However, its short half-life and undesirable tumor targeting ability has limited its usage in tumor treatment. In this work, two types of functional peptides, half-life extension peptide PAS, and tumor targeting peptide RGDK (Arg-Gly-Asp-Lys), are inserted to human heavy-chain ferritin (HFn) at C-terminal through flexible linkers with two distinct enzyme cleavable sites. Structural characterizations show both HFn and engineered HFns can assemble into nanoparticles but with different apparent hydrodynamic volumes and molecular weights. RGDK pept..

View full abstract

University of Melbourne Researchers

Grants

Awarded by National Natural Science Foundation of China


Awarded by Beijing Natural Science Foundation


Funding Acknowledgements

This work was funded by joint PhD Scholarship Scheme of the University of Adelaide and Institute of Process Engineering, Chinese Academy of Sciences, the National Natural Science Foundation of China [Grant No. 21576267], Beijing Natural Science Foundation [Grant Number 2162041], and Shanxi Education Science "1331 project" special research project (Research and Development of Traditional Chinese Medicine Micro-emulsion and New Biological Preparation).